glp-1 and rheumatoid arthritis Glucagon-like peptide its receptor agonists for the treatment of rheumatic diseases Stories like this are why
Description
82 The direct impact of GLP-1RAs on significant renal outcomes remains uncertain
It provides an alternative for patients absolutely averse to injections
This helps them avoid the intense side effects that happen when you restart a high dose after a break
As anti-obesity GLP-1s gain additional indications, patients and providers will be afforded even more pathways to access, especially in the Medicare channel
One flag = Moderate Risk
Treatment of sarcopenia with bimagrumab: Results from a phase II, randomized, controlled, proof-of-concept study
